4.8 Article

Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer

Journal

CELL METABOLISM
Volume 34, Issue 7, Pages 969-+

Publisher

CELL PRESS
DOI: 10.1016/j.cmet.2022.05.003

Keywords

-

Funding

  1. NIAAA [U01AA029019]
  2. NIEHS [5P42ES010337]
  3. NCATS [5UL1TR001442]
  4. NIDDK [U01DK130190, U01DK061734, R01DK106419, P30DK120515, R01DK121378, R01DK124318]
  5. NHLBI [P01HL147835]
  6. DOD PRCRP [W81XWH-18-2-0026]
  7. Arrowhead Pharmaceuticals
  8. AstraZeneca
  9. Boehringer-Ingelheim
  10. Bristol-Myers Squibb
  11. Eli Lilly
  12. Galectin Therapeutics
  13. Galmed Pharmaceuti-cals
  14. Gilead
  15. Intercept
  16. Hanmi
  17. Inventiva
  18. Ionis
  19. Janssen
  20. MadrigalPharmaceuticals
  21. Merck
  22. NGM Biopharmaceuticals
  23. Novo Nordisk
  24. Pfizer
  25. Sonic Incytes
  26. Terns Pharmaceuticals
  27. Singapore Ministry of Health's National Medical Research Council [MOH-000595-01]
  28. National Cancer Institute [R01 MD012565, U01 CA230694, R01 212008, R01 222900, R01 256977]
  29. NIH [1R01CA194307, 1R01CA215520-01, P30 DK 56338]
  30. GE Healthcare
  31. Canon Medical Systems Co.
  32. Lantheus Medical Imaging
  33. Bracco Diagnostics Inc.
  34. Cancer Prevention Research Institute of Texas [CAP-CAC RP190641]
  35. VA CSRD Merit Award [IIR 16I31.HB]

Ask authors/readers for more resources

Liver cancer epidemiology is changing due to factors such as increasing alcohol consumption, rising obesity rates, and advancements in hepatitis B and C treatment. The Global Burden of Disease study estimated global and regional trends in liver cancer burden, revealing a 25% increase in liver cancer deaths between 2010 and 2019. Non-alcoholic steatohepatitis (NASH) and alcohol were found to have the fastest growing death rates, while hepatitis B and C showed declines. Urgent measures are needed globally to address metabolic risk factors and slow the growing burden of NASH-associated liver cancer, particularly in the Americas.
Liver cancer epidemiology is changing due to increasing alcohol consumption, rising prevalence of obesity, and advances in hepatitis B virus (HBV) and hepatitis C virus (HCV) treatment. However, the impact of these changes on global liver cancer burden remains unclear. We estimated global and regional temporal trends in the burden of liver cancer and the contributions of various liver disease etiologies using the methodology framework of the Global Burden of Disease study. Between 2010 and 2019, there was a 25% increase in liver cancer deaths. Age -standardized death rates (ASDRs) increased only in the Americas and remained stable or fell in all other regions. Between 2010 and 2019, non-alcoholic steatohepatitis (NASH) and alcohol had the fastest growing ASDRs, while HCV and HBV declined. Urgent measures are required at a global level to tackle underlying metabolic risk factors and slow the growing burden of NASH-associated liver cancer, especially in the Americas.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available